芪胶升白胶囊防治恶性肿瘤放化疗后骨髓抑制临床疗效Meta分析OACSTPCD

Objective To systematically evaluate the clinical efficacy of Qijiao Shengbai Capsules in the prevention and treatment of malignant tumor with myelosuppression after chemoradiotherapy,and to provide a reference for clinical medication.Methods Database such as CNKI,WanFang,VIP,SinoMed,PubMed,Web of Science and The Cochrane Library were searched from their inception of the database to April 22,2023 to collect the randomized controlled trials(RCT)related to Qijiao Shengbai Capsules in the prevention and treatment of malignant tumors with myelosuppression after chemoradiotherapy.The modified Jadad Scale was used to evaluate the quality of the included literature,and Meta-analysis was performed by the RevMan 5.4 software.Results A total of 25 RCTs involving 2 754 patients were included,including 1 466 cases in the experimental group and 1 288 cases in the control group.Meta-analysis results showed that the overall myelosuppression rate[OR=0.27,95% CI(0.21,0.35),P<0.000 01],grade Ⅲ-Ⅳ myelosuppression rate[OR=0.23,95% CI(0.16,0.34),P<0.000 01],leukocytes[MD=1.18,95% CI(0.98,1.38),P<0.000 01],platelets[MD=14.06,95% CI(12.95,15.16),P<0.000 01],hemoglobin[MD=0.98,95% CI(0.87,1.09),P<0.000 01],KPS score improvement rate[OR=2.65,95% CI(1.90,3.70),P<0.000 01],KPS score[MD=6.13,95% CI(4.48,7.79),P<0.000 01]were significantly better than those in the control group.Conclusion Qijiao Shengbai Capsules can effectively reduce the overall myelosuppression rate and grade Ⅲ-Ⅳ myelosuppression rate of malignant tumor patients after chemoradiotherapy,increase KPS score and levels of leukocytes,hemoglobin,and platelets,so as to improve myelosuppression.